Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

By R. Clynes, Terri L. Towers, L. Presta, J. Ravetch. Nature Medicine, 2000

2,967 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/a6f994de288fac4838bd0880db60e355ae6b6c3b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. (2010, background): “The Fc region of rituximab plays a critical role in triggering the cellular events that lead to Bcell elimination in vivo.(7,12,13) This region of the molecule can interact with complement protein C1q and FcγRs to trigger CDC and ADCC, respectively.”
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. (2007, background): “In contrast, in mice lacking the Fc receptor (FcR / ) much of the therapeutic effect of trastuzumab was lost, with only 29% tumour growth inhibition observed [22].”
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors (2011, background): “activating FcgR, cancer therapeutic Abs lose their effect on tumor growth (30), and in cancer patients FcgR polymorphisms directly impact therapeutic responses to Abs (31, 42, 43).”
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. (2006, background): “Adverse events Any adverse event 183 (88) 261 (85) Severe adverse event* 49 (23) 55 (18) Related adverse event† 77 (37) 119 (39) Serious adverse event 21 (10) 23 (7) Adverse event leading to withdrawal 2 ( 1) 8 (3) Death 0 0 Adverse events reported at a 5% incidence 183 (88) 261 (85) Rheumatoid arth”
The TRAIL apoptotic pathway in cancer onset, progression and therapy (2008, background): “Thus, activating Fc-receptor-mediated immune activation can be a great advantage of antibody-based therapy of tumour”
New aspects of natural-killer-cell surveillance and therapy of cancer (2002, background): “Nevertheless, studies with mouse and humanized mAbs have shown that they engage both activation (FcγRIII) and inhibitory (FcγRIIB) receptors on myeloid cells, rather than through NK cell”
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. (2009, background): “Activation of ADCC has been described as a major mechanism of action of trastuzumab (13, 14, 38) and the present study confirms that this is also a property of pertuzumab.”
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009, background): “As a result of antibody binding to the ERBB2 extracellular domain, trastuzumab causes antibody-dependent cell-mediated cytotoxicity (ADCC”
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014, background): “However, increasing evidence suggests a significant contribution of innate and adaptive immunity to trastuzumab efficacy [15–19].”
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. (2006, background): “Such strategies in the clinical setting could add more effective inhibition of the receptor tyrosine kinase to an additional important mechanism of action of trastuzumab thought to occur through immune effector cells (48).”
ERBB receptors and cancer: the complexity of targeted inhibitors (2005, background): “In xenograft models at least, this mechanism is relevant for the antitumour activity of ERBB2-targeted trastuzuma”
The EGF receptor family as targets for cancer therapy (2000, background): “This process is regulated by both activating and inhibitory receptors for antibody Oncogene molecules on e ector cells (Clynes et al., 2000).”